{"name":"Tiletamine","slug":"tiletamine","kind":"substance","abbreviations":[],"systematic":null,"aliases":["Tiletamina","2-(Ethylamino)-2-(2-thienyl)cyclohexanone","Cyclohexanone, 2-(ethylamino)-2-(2-thienyl)-","Tiletaminum","2-(Ethylamino)-2-(thiophen-2-yl)cyclohexan-1-one","238-031-9","Hsdb 7638","Prestwick0_001022","Prestwick1_001022","Prestwick2_001022"],"brands":[],"scraped":true,"has_structure":true,"cid":26533,"classes":[{"name":"n-methyl-d-aspartic acid receptor antagonist","href":"/class/n-methyl-d-aspartic_acid_receptor_antagonist"}],"families":[{"name":"cyclohexylamine","href":"/substituted/cyclohexylamine"}],"physical":[{"label":"Molecular mass","value":"223.34 g/mol","copyable":false},{"label":"Predicted LogP","value":"2","copyable":false}],"identifiers":[{"label":"Molecular formula","value":"C<sub>12</sub>H<sub>17</sub>NOS","copyable":true},{"label":"IUPAC name","value":"2-(ethylamino)-2-thiophen-2-ylcyclohexan-1-one","copyable":true},{"label":"SMILES","value":"CCNC1(CCCCC1=O)C2=CC=CS2","copyable":true},{"label":"InChI","value":"InChI=1S/C12H17NOS/c1-2-13-12(11-7-5-9-15-11)8-4-3-6-10(12)14/h5,7,9,13H,2-4,6,8H2,1H3","copyable":true},{"label":"InChIKey","value":"QAXBVGVYDCAVLV-UHFFFAOYSA-N","copyable":true},{"label":"CAS number","value":"14176-49-9","copyable":true},{"label":"UNII","value":"2YFC543249","copyable":true},{"label":"PubChem CID","value":"26533","copyable":true}],"pharmacokinetics":[{"label":"Metabolism","value":"Liver","copyable":false},{"label":"Excretion","value":"Kidneys","copyable":false},{"label":"Routes of administration","value":"IV, IM, SC, Other","copyable":false}],"toxicity":[],"dosing":null,"salts":[{"title":"Tiletamine hydrochloride","name":"hydrochloride","slug":"tiletamine_hydrochloride","drawn":true}],"esters":[],"chirality":"racemic","stereo_type":"enantiomer","optical_activity":"( + / - )","stereoisomers":[{"name":"Prestwick-13G03","href":"/substance/prestwick-13g03"},{"name":"(S)-Tiletamine","href":"/substance/%28s%29-tiletamine"}],"lipinski":{"passes":true,"violations":0},"reagents":[{"reagent":"Marquis","reacts":true,"colors":["#ffffff","#fd7322"],"description":"orange"},{"reagent":"Mecke","reacts":true,"colors":["#ffffff","#7aefa6","#8e563a","#8e563a","#020f69"],"description":"olive > slow dark blue"},{"reagent":"Mandelin","reacts":false,"colors":[],"description":"no color change"},{"reagent":"Liebermann","reacts":true,"colors":["#ffffff","#fd7322"],"description":"orange"},{"reagent":"Froehde","reacts":false,"colors":[],"description":"no color change"},{"reagent":"Morris","reacts":true,"colors":["#ff6fcf","#7aefa6"],"description":"pale green"},{"reagent":"Gallic","reacts":false,"colors":[],"description":"no color change"}],"atc":[],"mesh":[{"name":"Anesthetics, Dissociative","id":"M0001168"},{"name":"Anticonvulsants","id":"M0001382"}],"actives":[],"prodrugs":[],"codrug":false,"interactions":[{"target":"GRIN1","mechanisms":["shared target"],"partners":2,"contraindicated":0},{"target":"GRIN2A","mechanisms":["shared target"],"partners":2,"contraindicated":0},{"target":"GRIN2B","mechanisms":["shared target"],"partners":2,"contraindicated":0},{"target":"GRIN2C","mechanisms":["shared target"],"partners":2,"contraindicated":0},{"target":"GRIN2D","mechanisms":["shared target"],"partners":2,"contraindicated":0}],"mechanism":"Neurochemical interactions of tiletamine, a potent phencyclidine (PCP) receptor ligand, with the N-methyl-D-aspartate (NMDA)-coupled and -uncoupled PCP recognition sites were examined. Tiletamine potently displaced the binding of [3H]1-(2-thienyl)cyclohexylpiperidine with an IC50 of 79 nM without affecting sigma-, glycine, glutamate, kainate, quisqualate, or dopamine (DA) receptors. Like other PCP ligands acting via the NMDA-coupled PCP recognition sites, tiletamine decreased basal, harmaline-, and D-serine-mediated increases in cyclic GMP levels and induced stereotypy and ataxia. Tiletamine was nearly five times more potent than PCP at inhibiting the binding of 3-hydroxy[3H]PCP to its high-affinity NMDA-uncoupled PCP recognition sites. However, following parenteral administration, dizocilpine maleate (MK-801), ketamine, PCP, dexoxadrol, and 1-(2-thienyl)cyclohexylpiperidine HCl, but not tiletamine, increased rat pyriform cortical DA metabolism and/or release, a response modulated by the NMDA-uncoupled PCP recognition sites. Pretreatment with tiletamine did not attenuate the MK-801-induced increases in rat pyriform cortical DA metabolism, a result suggesting that tiletamine is not a partial agonist of the NMDA-uncoupled PCP recognition sites in this region. However, following intracerebroventricular administration (100-500 ug/rat), tiletamine increased pyriform cortical DA metabolism with a bell-shaped dose-response curve. These data indicate a differential interaction of tiletamine with the NMDA-coupled and -uncoupled PCP recognition sites. The paradoxical effects of tiletamine suggest that tiletamine might activate receptor(s) or neuronal pathways of unknown pharmacology.","side_effects":null,"effects":null,"usernotes":[],"erowid":[],"reddit":[],"legal":[{"jurisdiction":"Australia","status":"Schedule 4","act":null,"refs":[]},{"jurisdiction":"United States","status":"Schedule III (when combined with Zolazepam)","act":"Controlled Substances Act","refs":[]}],"members":[],"part_of":[],"links":[{"source":"Wikipedia","url":"https://en.wikipedia.org/wiki/Tiletamine"},{"source":"PubChem","url":"https://pubchem.ncbi.nlm.nih.gov/compound/26533"},{"source":"Wikidata","url":"https://www.wikidata.org/wiki/Q2083144"},{"source":"DrugBank","url":"https://go.drugbank.com/drugs/DB11549"},{"source":"ChEMBL","url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL2110703"},{"source":"ChEBI","url":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI%3A94356"},{"source":"Common Chemistry","url":"https://commonchemistry.cas.org/detail?cas_rn=14176-49-9"},{"source":"HMDB","url":"https://hmdb.ca/metabolites/HMDB0259091"},{"source":"KEGG","url":"https://www.kegg.jp/entry/D08596"},{"source":"EPA DSSTox","url":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID5048552"},{"source":"Effect Index","url":"https://www.effectindex.com/search?q=Tiletamine"},{"source":"UNII","url":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/2YFC543249"}],"references":["National Center for Biotechnology Information. PubChem Compound Summary for CID 26533, Tiletamine. Accessed November 20, 2026. <a href=https://pubchem.ncbi.nlm.nih.gov/compound/26533>https://pubchem.ncbi.nlm.nih.gov/compound/26533</a>","U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Tiletamine. UNII: 2YFC543249. Global Substance Registration System. Accessed November 20, 2026. <a href=https://gsrs.ncats.nih.gov/ginas/app/beta/substances/2YFC543249>https://gsrs.ncats.nih.gov/ginas/app/beta/substances/2YFC543249</a>"],"sources":[{"source":"dosing","status":"missing","fetched_at":"2026-11-20 08:59:18","note":"no dosing statistics"},{"source":"drugspro","status":"ok","fetched_at":"2026-11-20 08:59:14","note":null},{"source":"erowid","status":"missing","fetched_at":"2026-11-20 08:59:14","note":"no Erowid substance of that name"},{"source":"gsrs","status":"ok","fetched_at":"2026-11-20 08:59:15","note":null},{"source":"hmdb","status":"missing","fetched_at":"2026-11-20 08:59:14","note":"hmdb.ca refused automated access to HMDB0259091"},{"source":"kegg","status":"ok","fetched_at":"2026-11-20 08:59:15","note":null},{"source":"pubchem","status":"ok","fetched_at":"2026-11-20 08:59:11","note":null},{"source":"reddit","status":"missing","fetched_at":"2026-11-20 08:59:14","note":"no r/tripreports posts mention it"},{"source":"sider","status":"missing","fetched_at":"2026-11-20 08:59:14","note":"not in SIDER"},{"source":"structure","status":"ok","fetched_at":"2026-11-20 08:59:14","note":null},{"source":"wikipedia","status":"ok","fetched_at":"2026-11-20 08:59:14","note":null}],"description":"Tiletamine is a n-methyl-d-aspartic acid receptor antagonist substance."}